ArticleMolecular cancer2019
Pan-cancer analysis identifies telomerase-associated signatures and cancer subtypes.
Article in Molecular cancer, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 53 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
53 citing papers in PubMed, 95 citations in OpenAlex.
- Telomere Maintenance Characteristics Predict Prognosis and Therapeutic Response in Colorectal Cancer.Current topics in medicinal chemistry · 2026Article
- Precision Oncology: Current Landscape, Emerging Trends, Challenges, and Future Perspectives.Cells · 2025Review
- Integrative analysis of ceRNA networks and immune cell infiltration in thyroid cancer for enhanced diagnostic and prognostic insights.Scientific reports · 2025Article
- Overexpression of the TPX2 gene is associated with enhanced tumor malignancy in lung adenocarcinoma and identification of marine natural inhibitors of the Aurora kinase A-TPX2 protein complex.In silico pharmacology · 2025Article
- Stratification of telomerase activity in cancer reveals associations with senescence and genomic instability.Computational and structural biotechnology journal · 2025Article
- Bioinformatics analysis reveals that CBX2 promotes enzalutamide resistance in prostate cancer.European journal of medical research · 2024Article
- Advances in prognostic models for osteosarcoma risk.Heliyon · 2024Review
- Emerging roles of circular RNAs in regulating the hallmarks of thyroid cancer.Cancer gene therapy · 2024Review
- Unlocking longevity: the role of telomeres and its targeting interventions.Frontiers in aging · 2024Review
- Ginsenosides and Tumors: A Comprehensive and Visualized Analysis of Research Hotspots and Antitumor Mechanisms.Journal of Cancer · 2024Article
- Reconstructing the immunosenescence core pathway reveals global characteristics in pan-cancer.Cancer immunology, immunotherapy : CII · 2023Article
- The potential bioactive ingredients and hub genes of five TCM prescriptions against lung adenocarcinoma were explored based on bioinformatics.Naunyn-Schmiedeberg's archives of pharmacology · 2023Article
- GEMIN4, a potential therapeutic targets for patients with basal-like subtype breast cancer.BMC women's health · 2023Article
- AhRR and PPP1R3C: Potential Prognostic Biomarkers for Serous Ovarian Cancer.International journal of molecular sciences · 2023Article
- Genomic, epigenomic, and transcriptomic signatures for telomerase complex components: a pan-cancer analysis.Molecular oncology · 2023Article
- Cancer-associated fibroblasts refine the classifications of gastric cancer with distinct prognosis and tumor microenvironment characteristics.Frontiers in oncology · 2023Article
- Bioinformatics Analysis and Experimental Study of Exonuclease 1 Gene in Lung Adenocarcinoma.Biochemical genetics · 2022Article
- Identification of Immune-Related Markers in Hepatocellular Carcinoma Based on Gene Co-expression Network.Biochemical genetics · 2022Article
- Towards a potential pan-cancer prognostic signature for gene expression based on probesets and ensemble machine learning.BioData mining · 2022Article
- AHNAK2 is a biomarker and a potential therapeutic target of adenocarcinomas.Acta biochimica et biophysica Sinica · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCancer cells become immortalized through telomere maintenance mechanisms, such as telomerase reverse transcriptase (TERT) activation. In addition to maintaining telomere length, TERT activates manifold cell survival signaling pathways. However, telomerase-associated gene signatures in cancer remain elusive.
methodsWe performed a systematic analysis of TERT high (TERT
resultsThe TERT
conclusionsIn summary, our results depict a telomerase-associated molecular landscape in cancers and provide therapeutic opportunities for cancer treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.